Macrolide Resistance in B-Hemolytic Streptococci: Changes after the Implementation of the Separation of Prescribing and Dispensing of Medications Policy in Korea|RISS 상세보기

다국어 초록 (Multilingual Abstract)

This study evaluated the antimicrobial susceptibilities and macrolide resistance mechanisms of beta-hemolytic streptococci (BHS), and an additional objective was to assess the effects of ‘the separation of prescribing and dispensing (SPD) of medications' on bacterial resistance rate and distribution of phenotypes and genotypes of erythromycin-resistant BHS by comparing the antimicrobial susceptibility data before (1990- 2000) and after the implementation of SPD at one tertiary care hospital in South Korea. Between the period of January 2001 and December 2002, the minimal inhibitory concentrations of six antimicrobials were determined for 249 clinical isolates of BHS. Resistance mechanisms of erythromycin-resistant (intermediate and resistant) isolates were studied by using the double disk test and PCR. Overall, the resistance rates to tetracycline, erythromycin, and clindamycin were 75.5%, 32.9%, and 32.5%, respectively. Sixty-seven (81.7%) of 82 erythromycin- resistant isolates expressed constitutive resistance to macrolide- lincosamide-streptogramin B antibiotics (a constitutive MLSB phenotype); 11 isolates (13.4%) expressed an M phenotype; and four isolates (4.9%) had an inducible MLSB resistance phenotype. erm(A) was found in isolates with constitutive/ inducible MLSB phenotypes, erm(B) with the constitutive/ inducible MLSB phenotype, and mef(A) with the M phenotype. We found that resistance rates to erythromycin and clindamycin among S. agalactiae, S. pyogenes, and group C streptococci isolates were still high after the implementation of the SPD policy in Korea, and that the constitutive MLSB resistance phenotype was dominant among erythromycin- resistant BHS in this Korean hospital.

번역하기

참고문헌 (Reference)

1 "Three different phenotypes of erythromycin-resistant Streptococcus pyogenes in Finland" 32 : 885-891, 1993

2 "The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland" 337 : 441-446, 1997

3 "The Spanish Surveillance Group for Respiratory Pathogens. Antimicrobial resistance of 914 beta- hemolytic streptococci isolated from pharyngeal swabs in Spain: results of a 1-year (1996-1997) multicenter surveillance study" 43 : 178-180, 1999

4 "Telithromycin and quinupristin-dalfopristin resistance in clinical isolates of Streptococcus pyogenes: SMART Program 2001 Data" 47 : 2152-2157, 2003

5 "Susceptibility to telithromycin in 1,011 Streptococcus pyogenes isolates from 10 central and eastern European countries" 46 : 546-549, 2002

6 "Susceptibility of beta-hemolytic streptococci to nine antimicrobial agents among four medical centers in Salt Lake City, Utah, USA" 27 : 123-128, 1997

7 "Streptococcus. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, editors. Manual of clinical microbiology" Washington, D.C: American Society for Microbiology 283-296, 1999

8 "Streptococcus pyogenes collected in Torino (northwest Italy) between 1983 and 1998: Survey of macrolide resistance and trend of genotype by RAPD" 6 : 289-295, 2000

9 "Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system" 40 : 1817-1824, 1996

10 "Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis" 35 : 113-125, 2002